Axion BioSystems is a leading life sciences tools company focused on innovative live-cell assays used to study the function of cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of new technologies that accelerate research and further the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and has offices in the Netherlands, the UK, and China.
ISTAND acceptance marks the first stem cell-derived functional cardiac safety assay to enter the program, reflecting FDA interest in human-relevant, non-animal approaches to assessing proarrhythmic risk.